Amicus Therapeutics Inc
F:AM6
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Amicus Therapeutics Inc
F:AM6
|
US |
Intrinsic Value
The intrinsic value of Amicus Therapeutics Inc (AM6) under the Base Case is 10.803 EUR per share. Compared with the current market price of 12.295 EUR, the stock appears Overvalued by 12% .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Amicus Therapeutics Does
Amicus Therapeutics is a biotechnology company that develops and sells treatments for rare genetic diseases, especially lysosomal storage disorders. Its main medicines are for people with Fabry disease and Pompe disease, two serious inherited conditions that can damage organs and make everyday life difficult. The company works with doctors, specialty pharmacies, and health systems that treat these patients.
- Headquarters
- United States of America US
- Employees
- 496
- IPO date
- May 31, 2007
Revenue & Expenses Breakdown
Amicus Therapeutics Inc
Earnings Waterfall
Amicus Therapeutics Inc
The intrinsic value for Amicus Therapeutics Inc (AM6) under the Base Case is 10.803 EUR.
Compared with the current market price of 12.295 EUR, the stock appears Overvalued by 12% .